{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:15:34Z","timestamp":1792649734519,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA182910"],"award-info":[{"award-number":["UM1 CA182910"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA173640"],"award-info":[{"award-number":["UM1 CA173640"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Using time-dependent Cox regression models, we examined associations of common antihypertensive medications with overall cancer survival (OS) and disease-specific survival (DSS), with comprehensive adjustment for potential confounding factors. Participants were from the Shanghai Women\u2019s Health Study (1996\u20132000) and Shanghai Men\u2019s Health Study (2002\u20132006) in Shanghai, China. Included were 2,891 incident breast, colorectal, lung, and stomach cancer cases. Medication use was extracted from electronic medical records. With a median 3.4-year follow-up after diagnosis (interquartile range, 1.0\u20136.3), we found better outcomes among users of angiotensin II receptor blockers with colorectal cancer (OS: adjusted hazard ratio (HR) = 0.62, 95% confidence interval (CI): 0.44, 0.86; DSS: adjusted HR = 0.61, 95% CI: 0.43, 0.87) and stomach cancer (OS: adjusted HR = 0.62, 95% CI: 0.41, 0.94; DSS: adjusted HR = 0.63, 95% CI: 0.41, 0.98) and among users of \u03b2-adrenergic receptor blockers with colorectal cancer (OS: adjusted HR = 0.50, 95% CI: 0.35, 0.72; DSS: adjusted HR = 0.50, 95% CI: 0.34, 0.73). Better survival was also found for calcium channel blockers (DSS: adjusted HR = 0.67, 95% CI: 0.47, 0.97) and diuretics (OS: adjusted HR = 0.66, 95% CI: 0.45, 0.96; DSS: adjusted HR = 0.57, 95% CI: 0.38, 0.85) with stomach cancer. Our findings suggest angiotensin II receptor blockers, \u03b2-adrenergic receptor blockers, and calcium channel blockers might be associated with improved survival outcomes of gastrointestinal cancers.<\/jats:p>","DOI":"10.1093\/aje\/kwz106","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:15:05Z","timestamp":1556219705000},"page":"1512-1528","source":"Crossref","is-referenced-by-count":50,"title":["Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer"],"prefix":"10.1093","volume":"188","author":[{"given":"Yong","family":"Cui","sequence":"first","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Tongren Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"},{"name":"Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tang","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"},{"name":"Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cai","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrong","family":"You","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"},{"name":"Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bing","family":"Xiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"},{"name":"Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-8314","authenticated-orcid":false,"given":"Xiao-Ou","family":"Shu","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"8","key":"2019080108003681200_kwz106C1","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019080108003681200_kwz106C2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019080108003681200_kwz106C3","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"2019080108003681200_kwz106C4","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"8 suppl B","key":"2019080108003681200_kwz106C5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"11","key":"2019080108003681200_kwz106C6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019080108003681200_kwz106C7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019080108003681200_kwz106C8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/OTT.S38403","article-title":"\u03b2-blockers: a novel class of antitumor agents","volume":"5","author":"Ji","year":"2012","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2019080108003681200_kwz106C9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tips.2011.02.008","article-title":"Previously unsuspected widespread cellular and tissue distribution of \u03b2-adrenoceptors and its relevance to drug action","volume":"32","author":"Daly","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"3\u20134","key":"2019080108003681200_kwz106C10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000163851","article-title":"Upregulation of beta3-adrenergic receptor mRNA in human colon cancer: a preliminary study","volume":"75","author":"Perrone","year":"2008","journal-title":"Oncology"},{"issue":"4","key":"2019080108003681200_kwz106C11","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.18632\/oncotarget.14119","article-title":"Use of non-selective \u03b2-blockers is associated with decreased tumor proliferative indices in early stage breast cancer","volume":"8","author":"Montoya","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2019080108003681200_kwz106C12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.30062","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis","volume":"139","author":"Raimondi","year":"2016","journal-title":"Int J Cancer"},{"key":"2019080108003681200_kwz106C13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-016-0782-5","article-title":"Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts","volume":"18","author":"Cardwell","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2019080108003681200_kwz106C14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clbc.2015.07.001","article-title":"\u03b2-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis","volume":"15","author":"Childers","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"2019080108003681200_kwz106C15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000455143","article-title":"Is beta-blocker use beneficial in breast cancer? A meta-analysis","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"issue":"1","key":"2019080108003681200_kwz106C16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","article-title":"The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis","volume":"26","author":"Song","year":"2017","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"2019080108003681200_kwz106C17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"issue":"13","key":"2019080108003681200_kwz106C18","doi-asserted-by":"crossref","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Evidence from a meta-analysis including 55 studies","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2019080108003681200_kwz106C19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"2019080108003681200_kwz106C20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2553-7","article-title":"Beta blockers and angiotensin converting enzyme inhibitors\u2019 purported benefit on breast cancer survival may be explained by aspirin use","volume":"139","author":"Holmes","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2019080108003681200_kwz106C21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"11","key":"2019080108003681200_kwz106C22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/aje\/kwi322","article-title":"The Shanghai Women\u2019s Health Study: rationale, study design, and baseline characteristics","volume":"162","author":"Zheng","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2019080108003681200_kwz106C23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ije\/dyv013","article-title":"Cohort profile: the Shanghai Men\u2019s Health Study","volume":"44","author":"Shu","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2019080108003681200_kwz106C24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oxfordjournals.aje.a009034","article-title":"Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale","volume":"145","author":"Korn","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2019080108003681200_kwz106C25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/ije\/dyu105","article-title":"Avoiding blunders involving \u2018immortal time\u2019","volume":"43","author":"Hanley","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2019080108003681200_kwz106C26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jclinepi.2005.08.007","article-title":"Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods","volume":"59","author":"Grunau","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2019080108003681200_kwz106C27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag\u2010time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"19","key":"2019080108003681200_kwz106C28","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/djt211","article-title":"Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival","volume":"105","author":"Chubak","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019080108003681200_kwz106C29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/apt.14388","article-title":"Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study","volume":"47","author":"Busby","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"446","key":"2019080108003681200_kwz106C30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"19","key":"2019080108003681200_kwz106C31","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019080108003681200_kwz106C32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4143\/crt.2017.591","article-title":"Diabetes medication use in association with survival among patients of breast, colorectal, lung, or gastric cancer","volume":"51","author":"Baglia","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"5","key":"2019080108003681200_kwz106C33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1593\/tlo.13346","article-title":"Exposure to ACEI\/ARB and \u03b2-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer","volume":"6","author":"Engineer","year":"2013","journal-title":"Transl Oncol"},{"issue":"6","key":"2019080108003681200_kwz106C34","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"2019080108003681200_kwz106C35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1741-7015-12-28","article-title":"Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts","volume":"12","author":"Cardwell","year":"2014","journal-title":"BMC Med"},{"issue":"7","key":"2019080108003681200_kwz106C36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7150\/jca.6888","article-title":"Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes","volume":"4","author":"Chae","year":"2013","journal-title":"J Cancer"},{"key":"2019080108003681200_kwz106C37","doi-asserted-by":"crossref","first-page":"21359","DOI":"10.1038\/srep21359","article-title":"Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC","volume":"6","author":"Miao","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"2019080108003681200_kwz106C38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cllc.2014.09.006","article-title":"Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy","volume":"16","author":"Wang","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"2019080108003681200_kwz106C39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.28546","article-title":"Stage-specific associations between beta blocker use and prognosis after colorectal cancer","volume":"120","author":"Jansen","year":"2014","journal-title":"Cancer"},{"issue":"19","key":"2019080108003681200_kwz106C40","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: a population-based study","volume":"29","author":"Barron","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019080108003681200_kwz106C41","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/ije\/dyt196","article-title":"Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort","volume":"42","author":"Cardwell","year":"2013","journal-title":"Int J Epidemiol"},{"key":"2019080108003681200_kwz106C42","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic \u03b2-blocker use and lung cancer survival: a population-based cohort study","volume":"7","author":"Weberpals","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"2019080108003681200_kwz106C43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10654-017-0304-5","article-title":"Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis","volume":"32","author":"Weberpals","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"2019080108003681200_kwz106C44","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","article-title":"Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population","volume":"26","author":"Chen","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"2019080108003681200_kwz106C45","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","article-title":"Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study","volume":"31","author":"S\u00f8rensen","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019080108003681200_kwz106C46","first-page":"3917","article-title":"No association between calcium channel blockers and survival in patients with cancer: a systematic review and meta-analysis","volume":"17","author":"Sun","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2019080108003681200_kwz106C47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/EDE.0000000000000814","article-title":"Postdiagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study","volume":"29","author":"Busby","year":"2018","journal-title":"Epidemiology"},{"issue":"5","key":"2019080108003681200_kwz106C48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10552-017-0867-1","article-title":"History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium","volume":"28","author":"Minlikeeva","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2019080108003681200_kwz106C49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwz106\/28891440\/kwz106.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/188\/8\/1512\/29021761\/kwz106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T22:06:10Z","timestamp":1663365970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/188\/8\/1512\/5486396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,7]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwz106","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,7]]}}}